|
Median Age (range) – yr.
|
48 (14–77)
|
|
Sex – no. (%)
|
|
Male
|
133 (55)
|
|
Female
|
110 (45)
|
|
Primary Site – no. (%)
|
|
Cutaneous
|
188 (77)
|
|
H&N
|
34 (14)
|
|
LE
|
38 (16)
|
|
UE
|
29 (12)
|
|
Breast
|
1 (<1)
|
|
Trunk – anterior/posterior
|
74 (30)
|
|
Unknown
|
12 (5)
|
|
Mucosal
|
14 (6)
|
|
GI - anorectal
|
3 (1)
|
|
Aerodigestive
|
3 (1)
|
|
Urethral
|
1 (<1)
|
|
Vulva
|
7 (3)
|
|
Unknown
|
24 (10)
|
|
Uveal (choroid)
|
16 (7)
|
|
Other (orbit)
|
1 (<1)
|
|
Metastatic status prior to HD IL-2 – no. (%)
|
|
Skin, subcutaneous, LN (M1a)
|
43 (18)
|
|
Lung (M1b)
|
58 (24)
|
|
Non-lung visceral (M1c non-CNS)
|
99 (41)
|
|
CNS (M1c CNS)
|
43 (18)
|
|
LDH – no. (%)
|
|
Normal
|
106 (44)
|
|
Abnormal
|
137 (56)
|
|
1xULN-2xULN
|
74 (30)
|
|
> 2xULN
|
63 (26)
|
|
Protocol – no. (%)
|
|
Standard of care (SOC)
|
193 (79)
|
|
HD IL-2/temozolomide
|
30 (12)
|
|
HD IL-2+/− ziv-aflibercept (HD IL-2 alone)
|
20 (8)
|
|
Line of therapy – no. (%)
|
|
1st line
|
114 (47)
|
|
2nd line
|
83 (34)
|
|
3rd line or subsequent line
|
46 (19)
|
|
Pre-HD IL-2 therapies* – no. (%)
|
|
CTLA-4 inhibitor
|
20 (8)
|
|
PD-1 inhibitor
|
2 (1)
|
|
Other immunotherapies (including biochemotherapy)
|
73 (30)
|
|
BRAFi/MEKi target therapy
|
3 (1)
|
|
Other targeted therapy
|
13 (5)
|
|
Chemotherapy
|
54 (22)
|
|
Post-progression therapies* – no. (%)
|
|
CTLA-4 inhibitor
|
29 (12)
|
|
PD-1 inhibitor
|
11 (5)
|
|
Other immunotherapies (including biochemotherapy)
|
29 (12)
|
|
BRAFi/MEKi target therapy
|
12 (5)
|
|
Other targeted therapy
|
5 (2)
|
|
Chemotherapy
|
43 (18)
|
